Advertisement
Search for

Volume 7, Issue 9, Pages 972-980.e2 (September 2009)


View previous. 26 of 33 View next.

Linking Article with GastroenterologyAdditional Online Content AvailableGenetic Risk Profiling and Prediction of Disease Course in Crohn's Disease Patients

Liesbet HenckaertsCorresponding Author Informationemail address, Kristel Van Steen§, Isabel Verstreken, Isabelle Cleynen, Andre Franke#, Stefan Schreiber#⁎⁎, Paul Rutgeerts, Séverine Vermeire

published online 08 May 2009.

Refers to article:
Video AbstractAdditional Online Content AvailableLinking Article with CGH Analysis of HLA and Non-HLA Alleles Can Identify Individuals at High Risk for Celiac Disease , 18 May 2009
Jihane Romanos, Cleo C. van Diemen, Ilja M. Nolte, Gosia Trynka, Alexandra Zhernakova, Jingyuan Fu, Maria Teresa Bardella, Donatella Barisani, Ross McManus, David A. van Heel, Cisca Wijmenga
Gastroenterology
September 2009 (Vol. 137, Issue 3, Pages 834-840.e3)
Abstract | Full Text | Full-Text PDF (1182 KB) | Add-Ons
Background & Aims

Clinical presentation at diagnosis and disease course of Crohn's disease (CD) are heterogeneous and variable over time. Early introduction of immunomodulators and/or biologicals might be justified in patients at risk for disease progression, so it is important to identify these patients as soon as possible. We examined the influence of recently discovered CD-associated susceptibility loci on changes in disease behavior and evaluated whether a genetic risk model for disease progression could be generated.

Methods

Complete medical data were available for 875 CD patients (median follow-up time, 14 years; interquartile range, 7–22). Fifty CD-associated polymorphisms were genotyped. Kaplan–Meier survival analyses, multiple logistic regression, and generalized multifactor dimensionality reduction analyses (GMDR) were performed, correcting for follow-up time.

Results

Homozygosity for the rs1363670 G-allele in a gene encoding a hypothetical protein near the IL12B gene was independently associated with stricturing disease behavior (odds ratio [OR], 5.48; 95% confidence interval [CI], 1.60–18.83; P = .007) and with shorter time to strictures (P = .01), especially in patients with ileal involvement (P = .0002). Male patients carrying at least one rs12704036 T-allele in a gene desert had the shortest time to non-perianal fistula (P < .0001). The presence of a C-allele at the CDKAL1 single nucleotide polymorphism rs6908425 and the absence of NOD2 variants were independently associated with development of perianal fistula (OR, 8.86; 95% CI, 1.13–69.78; P = .04 and OR, 0.56; 95% CI, 0.38–0.83; P = .004, respectively), particularly when colonic involvement and active smoking were present.

Conclusions

CD-associated polymorphisms play a role in disease progression and might be useful in identifying patients who could benefit from an early top-down treatment approach.

 Department of Medicine, Gastroenterology Section, Catholic University of Leuven, Leuven, Belgium

 Montefiore Institute, Department of Electrical Engineering and Computer Science/Bioinformatics, University of Liège, Liège, Belgium

§ StepGen cvba, Merelbeke, Belgium

 Department of Human Genetics, Catholic University of Leuven, Leuven, Belgium

 Department of Laboratory Medicine, Catholic University of Leuven, Leuven, Belgium

# Institute for Clinical Molecular Biology, University Hospital Schleswig-Holstein, Christian-Albrechts-University, Kiel, Germany

⁎⁎ Department of General Internal Medicine, University Hospital Schleswig-Holstein, Christian-Albrechts-University, Kiel, Germany

Corresponding Author InformationReprint requests Address requests for reprints to: Liesbet Henckaerts, MD, PhD, Herestraat 49, B-3000 Leuven, Belgium. fax: (32) 16-34-43-99

 Conflicts of interest The authors disclose no conflicts.

 Funding L. Henckaerts is a doctoral fellow and S. Vermeire is a clinical researcher of the Fund for Scientific Research (FWO), Flanders, Belgium. A. Franke was supported by the German Ministry of Education and Research (BMBF) through the National Genome Research Network (NGFN) and received infrastructure support through the DFG excellence cluster “Inflammation at Interfaces.”

PII: S1542-3565(09)00435-2

doi:10.1016/j.cgh.2009.05.001


View previous. 26 of 33 View next.

Advertisement